Alzheimer's Disease News and Research

RSS
Alzheimer's disease (AD) is an irreversible, progressive brain disease that slowly destroys memory and thinking skills and, eventually, the ability to carry out the simplest tasks of daily living. In most people with AD, symptoms first appear after age 60. AD is the most common cause of dementia among older people, but it is not a normal part of aging. Dementia refers to a decline in cognitive function that interferes with daily life and activities. AD starts in a region of the brain that affects recent memory, then gradually spreads to other parts of the brain. Although treatment can slow the progression of AD and help manage its symptoms in some people, currently there is no cure for this devastating disease.
Research highlights potential of blood epigenetics for dementia risk assessment

Research highlights potential of blood epigenetics for dementia risk assessment

PET imaging and proteomics reveal distinct protein signatures in Alzheimer's disease progression

PET imaging and proteomics reveal distinct protein signatures in Alzheimer's disease progression

Dementia Australia welcomes UK approval of lecanemab to tackle Alzheimer’s

Dementia Australia welcomes UK approval of lecanemab to tackle Alzheimer’s

Acute kidney injury linked to increased risk of dementia

Acute kidney injury linked to increased risk of dementia

Exploring early detection of Alzheimer's disease through non-cognitive symptoms

Exploring early detection of Alzheimer's disease through non-cognitive symptoms

Multiple sclerosis patients less likely to have molecular hallmarks of Alzheimer's disease

Multiple sclerosis patients less likely to have molecular hallmarks of Alzheimer's disease

Cholinesterase inhibitors may slow cognitive decline in dementia with Lewy bodies

Cholinesterase inhibitors may slow cognitive decline in dementia with Lewy bodies

FDA-approved drug could revolutionize organ transplantation

FDA-approved drug could revolutionize organ transplantation

Kynurenine pathway blockade shows promise for restoring brain metabolism in Alzheimer's

Kynurenine pathway blockade shows promise for restoring brain metabolism in Alzheimer's

Cancer drug holds promise as a new treatment for neurodegenerative diseases

Cancer drug holds promise as a new treatment for neurodegenerative diseases

Study shows frequent mitochondrial DNA insertion in the brain cells

Study shows frequent mitochondrial DNA insertion in the brain cells

UC Irvine researchers discover the neurons responsible for "item memory"

UC Irvine researchers discover the neurons responsible for "item memory"

Understanding gluten's role in autoimmunity and inflammation

Understanding gluten's role in autoimmunity and inflammation

New compound shows promise in Alzheimer’s preclinical models

New compound shows promise in Alzheimer’s preclinical models

Study reveals gaps in Alzheimer's knowledge

Study reveals gaps in Alzheimer's knowledge

NIH awards $6.9 million  to prepare a potential Alzheimer's treatment for future clinical trials

NIH awards $6.9 million to prepare a potential Alzheimer's treatment for future clinical trials

Study reveals genetic link between Alzheimer's disease, lipid metabolism, and coronary artery disease

Study reveals genetic link between Alzheimer's disease, lipid metabolism, and coronary artery disease

USC researchers develop new sleep analysis tool based on heart data

USC researchers develop new sleep analysis tool based on heart data

Lecanemab effectively targets amyloid plaques in people with Down syndrome, study finds

Lecanemab effectively targets amyloid plaques in people with Down syndrome, study finds

New Springer textbook provides a comprehensive overview of aging science

New Springer textbook provides a comprehensive overview of aging science

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.